• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by NovoCure Limited

    5/21/26 4:00:26 PM ET
    $NVCR
    Medical/Dental Instruments
    Health Care
    Get the next $NVCR alert in real time by email
    DEFA14A 1 defa-14a2026proxyprop4mate.htm DEFA14A Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    ______________________________________________
    SCHEDULE 14A
    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934
    (Amendment No. ) 
    ______________________________________________
    Filed by the Registrant ☑Filed by a Party other than the Registrant ☐
    Check the appropriate box:
    ☐Preliminary Proxy Statement
    ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐Definitive Proxy Statement
    ☑Definitive Additional Materials
    ☐Soliciting Material under § 240.14a-12
    NovoCure Limited
    (Name of Registrant as Specified In Its Charter)
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)
    Payment of Filing Fee (Check the appropriate box):
    ☑No fee required.
    ☐Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
    (1)
    Title of each class of securities to which transaction applies:

    (2)
    Aggregate number of securities to which transaction applies:

    (3)
    Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

    (4)
    Proposed maximum aggregate value of transaction:

    (5)
    Total fee paid:

    ☐Fee paid previously with preliminary materials.
    ☐Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
    (1)
    Amount Previously Paid:

    (2)
    Form, Schedule or Registration Statement No.:

    (3)
    Filing Party:

    (4)
    Date Filed:






    slide1a.jpgslide2a.jpg




    slide3a.jpgslide4a.jpg




    slide5a.jpgslide6a.jpg




    slide7a.jpgslide8a.jpg




    slide9a.jpgslide10a.jpg




    slide11a.jpgslide12a.jpg


    Get the next $NVCR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NVCR

    DatePrice TargetRatingAnalyst
    7/25/2025$14.50Overweight → Equal Weight
    Wells Fargo
    7/8/2025$30.00Buy
    Ladenburg Thalmann
    12/2/2024$18.00 → $30.00In-line → Outperform
    Evercore ISI
    10/16/2024$24.00 → $30.00Neutral → Buy
    H.C. Wainwright
    11/20/2023$15.00Neutral
    JP Morgan
    8/28/2023$85.00 → $25.00Buy → Neutral
    H.C. Wainwright
    8/8/2023$45.00Neutral → Overweight
    Piper Sandler
    8/4/2023$51.00Outperform
    SVB Securities
    More analyst ratings

    $NVCR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Novocure Reports First Quarter 2026 Financial Results

    Quarterly net revenues of $174 million, up 12% year-over-year, driven by global growth in Optune Gio® Optune Pax® approved by the U.S. FDA and launched for the treatment of locally advanced pancreatic cancer; more than 800 prescribers certified and more than 160 prescriptions received through March 31, 2026 Novocure (NASDAQ:NVCR) today reported financial results for the first quarter that ended March 31, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). "This was a very strong start to the year for Novocure and we are pleased w

    4/30/26 7:00:00 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Novocure to Report First Quarter 2026 Financial Results

    Novocure (NASDAQ:NVCR) will report financial results for the first quarter 2026 on April 30, 2026, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, April 30, to discuss the company's financial results for the three-month period that ended March 31, 2026. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link. The slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of Novocure's website, www.novocure.com/invest

    4/1/26 7:00:00 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer

    Novocure (NASDAQ:NVCR) announced positive results today from the Phase 2 PANOVA-4 trial of Tumor Treating Fields (TTFields) therapy concomitant with atezolizumab (Tecentriq®), gemcitabine and nab-paclitaxel (gem/nab-pac) as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC). PANOVA-4 met its pre-specified primary endpoint, achieving a statistically significant improvement in disease control rate (DCR) compared to the DCR reported in the Phase 3 MPACT study used as the historical control.1 The DCR in patients treated with TTFields therapy concomitantly with atezolizumab and gem/nab-pac (N=78) was 74.4% compared to a DCR of 48% in patients receiving gem/nab-pac a

    3/26/26 7:00:00 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    $NVCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    NovoCure downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded NovoCure from Overweight to Equal Weight and set a new price target of $14.50

    7/25/25 8:59:40 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Ladenburg Thalmann initiated coverage on NovoCure with a new price target

    Ladenburg Thalmann initiated coverage of NovoCure with a rating of Buy and set a new price target of $30.00

    7/8/25 8:49:22 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    NovoCure upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded NovoCure from In-line to Outperform and set a new price target of $30.00 from $18.00 previously

    12/2/24 6:59:42 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    $NVCR
    SEC Filings

    View All

    SEC Form DEFA14A filed by NovoCure Limited

    DEFA14A - NovoCure Ltd (0001645113) (Filer)

    5/21/26 4:00:26 PM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    NovoCure Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NovoCure Ltd (0001645113) (Filer)

    4/30/26 7:01:40 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by NovoCure Limited

    10-Q - NovoCure Ltd (0001645113) (Filer)

    4/30/26 7:01:01 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    $NVCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Leung Gabriel sold $46,445 worth of Ordinary Shares (2,945 units at $15.77), decreasing direct ownership by 3% to 89,499 units (SEC Form 4) to satisfy withholding tax

    4 - NovoCure Ltd (0001645113) (Issuer)

    6/3/26 4:54:07 PM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Director Stafford Kristin sold $46,445 worth of Ordinary Shares (2,945 units at $15.77), decreasing direct ownership by 21% to 11,324 units (SEC Form 4) (withholding obligation)

    4 - NovoCure Ltd (0001645113) (Issuer)

    6/3/26 4:53:56 PM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Director Ocean Allyson J sold $46,445 worth of Ordinary Shares (2,945 units at $15.77), decreasing direct ownership by 21% to 11,324 units (SEC Form 4) to cover withholding tax

    4 - NovoCure Ltd (0001645113) (Issuer)

    6/3/26 4:53:42 PM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    $NVCR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 18, 2024 - FDA Roundup: October 18, 2024

    For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

    10/18/24 4:16:25 PM ET
    $NVCR
    $BAX
    Medical/Dental Instruments
    Health Care

    $NVCR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Cordova Ashley bought $996,859 worth of Ordinary Shares (81,550 units at $12.22), increasing direct ownership by 23% to 437,569 units (SEC Form 4)

    4 - NovoCure Ltd (0001645113) (Issuer)

    9/8/25 7:10:52 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Brackmann Christoph bought $231,800 worth of Ordinary Shares (20,000 units at $11.59), increasing direct ownership by 17% to 141,150 units (SEC Form 4)

    4 - NovoCure Ltd (0001645113) (Issuer)

    7/30/25 4:33:06 PM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    $NVCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NovoCure Limited

    SC 13G/A - NovoCure Ltd (0001645113) (Subject)

    7/10/24 1:14:41 PM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by NovoCure Limited

    SC 13G/A - NovoCure Ltd (0001645113) (Subject)

    7/8/24 4:32:39 PM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by NovoCure Limited (Amendment)

    SC 13G/A - NovoCure Ltd (0001645113) (Subject)

    2/13/24 5:09:51 PM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    $NVCR
    Financials

    Live finance-specific insights

    View All

    Novocure Reports First Quarter 2026 Financial Results

    Quarterly net revenues of $174 million, up 12% year-over-year, driven by global growth in Optune Gio® Optune Pax® approved by the U.S. FDA and launched for the treatment of locally advanced pancreatic cancer; more than 800 prescribers certified and more than 160 prescriptions received through March 31, 2026 Novocure (NASDAQ:NVCR) today reported financial results for the first quarter that ended March 31, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). "This was a very strong start to the year for Novocure and we are pleased w

    4/30/26 7:00:00 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Novocure to Report First Quarter 2026 Financial Results

    Novocure (NASDAQ:NVCR) will report financial results for the first quarter 2026 on April 30, 2026, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, April 30, to discuss the company's financial results for the three-month period that ended March 31, 2026. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link. The slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of Novocure's website, www.novocure.com/invest

    4/1/26 7:00:00 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

    Full year 2025 net revenues of $655 million and fourth quarter net revenues of $174 million Optune Pax® approved by the U.S. FDA for the treatment of locally advanced pancreatic cancer, commercial launch underway Novocure (NASDAQ:NVCR) today reported financial results for the quarter and full year ended December 31, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). "In 2025, a record number of patients received treatment with Novocure's Tumor Treating Fields therapy, a milestone that reflects our growth and commitment to advanc

    2/26/26 7:00:00 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    $NVCR
    Leadership Updates

    Live Leadership Updates

    View All

    Novocure Appoints Company President Frank Leonard as Chief Executive Officer

    Novocure (NASDAQ:NVCR) today announced the appointment of Frank Leonard as Chief Executive Officer (CEO), effective immediately. Mr. Leonard previously served as President of Novocure and succeeds Ashley Cordova who has resigned from the company. "During his more than 15-year career at Novocure, Frank has led many of our global business operations developing deep expertise in delivering our unique, device-based cancer therapy to patients to extend their survivals. Frank has been instrumental in creating Novocure's culture and guiding the organization at critical points, including preparing the company for its first commercial launch and establishing the business functions that continue to

    12/1/25 7:00:00 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Novocure Appoints Christoph Brackmann as Chief Financial Officer

    Novocure (NASDAQ:NVCR) announced today that Christoph Brackmann has been appointed as the company's next Chief Financial Officer (CFO). Mr. Brackmann will join Novocure immediately as a Senior Financial Advisor and will transition to the role of CFO on January 1, 2025 when current CFO, Ashley Cordova, becomes CEO. Mr. Brackmann joins Novocure from Moderna, Inc. where he served as Senior Vice President of Finance since 2019. While at Moderna he established and built the finance team and oversaw the rapid expansion of the organization during the COVID-19 pandemic. "The addition of Christoph to our Novocure executive team comes at a pivotal time for the organization as we expand our product

    10/30/24 7:02:00 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors

    Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board Masimo Corporation (NASDAQ:MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the "Board"), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, "We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals who will bring critical perspectives to the Board and possess expertise that closely aligns

    10/18/24 9:00:00 AM ET
    $ENV
    $LH
    $MASI
    Business Services
    Consumer Discretionary
    Medical Specialities
    Health Care